Peptilogics Inc.
Pittsburgh, PA
- UEI
- GQ3MK4JQYEK1
- CAGE
- 70T85
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 2681 Sidney St, Pittsburgh, PA 15203, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | -$326,200 | |
| Trustees Of Boston University | 75A50122C00028 | $1,520,300 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Debiopharm International SA | Lausanne, VD | — |
| Arietis Corporation | Boston, MA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Gangagen Biotechnologies Private LIMITED | Bengaluru, KA | — |
| Nubad LLC | Greer, SC | 541380 Testing Laboratories and Services |
| Entasis Therapeutics, Inc. | Waltham, MA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Peptilogics Inc. is a for-profit biotechnology company that provides peptide therapeutics to address unmet medical needs. Through federal contracts and grants, Peptilogics Inc. develops novel antimicrobial peptides to treat drug-resistant infections.
Peptilogics Inc. has provided research and development services as a subcontractor to Trustees of Boston University, the prime contractor, on a federal contract from an undisclosed funding agency. The contract work involves developing PLG0206, an engineered cationic antibiotic peptide candidate, to treat prosthetic joint infections. PLG0206 exhibits broad-spectrum antimicrobial activity against pathogens causing these biofilm-associated infections. The contract aims to assess PLG0206's safety and efficacy as an intraoperative irrigation solution to eradicate infection when administered during prosthetic joint revision surgery.
Through federal grants, Peptilogics Inc. has conducted research and development as a subrecipient to Trustees of Boston University, the prime grantee, to develop PLG0206 as a treatment for prosthetic joint infections. The company has tested PLG0206's antimicrobial effects against pathogens causing these infections. It also assessed the tolerability and efficacy of using PLG0206 as a local irrigation therapy in animal models. Additionally, Peptilogics Inc. has identified effective PLG0206 concentrations for testing in human trials. The grants intend to establish the safety and efficacy of local PLG0206 irrigation to treat prosthetic joint infections.
Quick answers
Is Peptilogics Inc. registered in SAM.gov?
Yes. Peptilogics Inc.'s SAM.gov registration is active through December 24, 2026.
On GovTribe
See Peptilogics Inc.'s full federal record
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors